What Is the Mechanism of Action of PLUVICTO?
PLUVICTO delivers DNA-breaking radiation directly to PSMA+ metastases.1
Learn how PLUVICTO works
Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
PLUVICTO targets PSMA+ cells regardless of where they have metastasized (bone, nodal, or visceral)1
PLUVICTO is comprised of 2 key components: Lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.1-3
PLUVICTO binds to PSMA, a transmembrane protein expressed in prostate cancer cells. After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.1,2,4
Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum, causes single- and double-stranded DNA breaks in targeted cells as well as surrounding cells, which can lead to cell death.1,5,6
PLUVICTO (plu-VIK-toh) describes a PSMA-targeted (P) lutetium-based (LU) radioligand therapy in PSMA+ mCRPC, where another option for patients is a victory1
Scanning to confirm PSMA+ mCRPC is key to identifying patients who may benefit from PLUVICTO1
Find information on PSMA-PET/CT scanning for your patients
CT, computed tomography; mCRPC, metastatic castration-resistant prostate cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.